QLGN - Qualigen Therapeutics Inc
Qualigen Therapeutics Inc Logo

QLGN - Qualigen Therapeutics Inc

https://qlgntx.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage

No recent news found.

AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Qualigen, Inc., a biotechnology company, develops new therapeutic products for the treatment of cancer and infectious diseases. The company is headquartered in Carlsbad, California.

52W High
$10.45
52W Low
$1.61

MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
-0.15
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
0.27
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.05
EV/Revenue (<3 favorable)
0.69
P/S (TTM) (<3 favorable)
0.39
P/B (<3 favorable)
0.41
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
2.18%
Institutions (25–75% balanced)
0.72%
Shares Outstanding
1,695,400
Float
1,695,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
4,983,600
Gross Profit (TTM)
1,043,000
EPS (TTM)
6.32
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-8.42%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.14
Momentum
Bearish momentum
Value
-0.0863
Previous
-0.1239
Trend
Rising
Signal Cross
No cross

As of
Sep. 12, 2025